Loading…
Loading…
EQUITY / NASDAQ · XNMS
Gain Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.73 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.73 USD · Volume 787,978
680 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -4,681,652 USD | — | — |
| Net income | -4,675,571 USD | — | — |
| Cash and cash equivalents | 13,084,144 USD | — | — |
| Total liabilities | 4,129,908 USD | — | — |
| Total equity | 11,292,031 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 13,084,144 USD | — | — | 16,539,222 USD | 20,837,628 USD | 20,837,628 USD | 8,807,353 USD | — |
| Net incomeIncome statement | -4,675,571 USD | -10,284,303 USD | — | -5,608,732 USD | — | -20,161,099 USD | -5,284,373 USD | -15,623,518 USD |
| Operating profitIncome statement | -4,681,652 USD | -10,035,197 USD | — | -5,353,545 USD | — | -18,710,702 USD | -4,785,777 USD | -14,244,679 USD |
| Total assetsBalance sheet | 15,421,939 USD | — | — | 18,738,464 USD | 22,818,975 USD | 22,818,975 USD | 10,971,680 USD | — |
| Total equityBalance sheet | 11,292,031 USD | — | 14,006,977 USD | 14,006,977 USD | 18,564,748 USD | 18,564,748 USD | 5,909,430 USD | — |
| Total liabilitiesBalance sheet | 4,129,908 USD | — | — | 4,731,487 USD | 4,254,227 USD | 4,254,227 USD | 5,062,250 USD | — |
| Financing cash flowCash flow statement | — | 1,770,383 USD | — | 404,321 USD | — | 28,447,766 USD | — | 11,896,585 USD |
| Operating cash flowCash flow statement | — | -9,407,532 USD | — | -4,727,527 USD | — | -18,465,432 USD | — | -13,846,945 USD |
| Report source | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 05/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 03/26/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.